The North America preimplantation genetic testing market is expected to reach USD 289.19 million by 2027 from USD 167.90 million in 2022, with a CAGR of 11.49% during the forecast period 2022 to 2027.
The growth of the market is mainly driven by the increasing rate of infertility in the world, the increasing number of fertility clinics in the world, public-private investments in the field of preimplantation genetic testing, technological advances in the field of genetic analysis and the high risk of chromosomal abnormalities in the fetus with increasing maternal age.
The North America preimplantation genetic testing market is expected to experience remarkable growth in the coming years due to the increasing prevalence of genetic, hereditary and chromosomal diseases. In addition, this testing has a high chance of conceiving healthy embryos. In the coming years, there will be an increase in the adoption of preimplantation genetic testing due to the various applications for the development of healthy embryos and it is expected that gender selection will increase due to the growing imbalance between the sexes.
The high procedural cost associated with pre-implant genetic testing and unfavorable government regulations are the key factors holding back the growth of the market. Increased awareness of preimplantation genetic testing and growing medical tourism will provide lucrative opportunities for market growth. Lack of knowledge about genetic testing, lack of reimbursement policies by insurance companies, and ethical concerns will challenge the rate of market growth in the United States and Canada.
This research report on the North America Preimplantation Genetic Testing Market has been segmented and sub-segmented into the following categories:
By Procedure Type:
By Products & Services:
By End User:
North America accounted for the largest share of the global preimplantation genetic testing market in 2019, followed by Europe. The high proportion in the North American region is mainly attributed to the increasing number of IVF procedures (with decreasing fertility rates), the high adoption of genomic techniques and the current trend to replace traditional genomic technologies with techniques that include advanced and innovative genetics tests such as POISSON and NGS. In addition, 3.31 million children under the age of five die each year from severe birth defects worldwide. But medical genetics services and effective interventions, especially in developing regions, could reduce disability and mortality by up to 75%. Hence, awareness of preimplantation genetic testing is driving the market.
The United States is expected to dominate the market for preimplantation genetic testing market. The prevalence is due to an increasing volume of cases of chromosomal abnormalities leading to various genetic disorders. Aneuploidy is the most common cause of Down syndrome in newborns in the United States, which accounts for the largest share of North American market income. According to the World Health Organization report released in 2018, trisomy 21 remains the most common chromosomal disease affecting 6,100 babies born in the United States each year.
This, in turn, has generated a strong demand for early diagnostics to identify genetic defects in embryos that fuel the market in the region. New product launches by major companies and increased improvements in healthcare infrastructure in the United States generate more revenue. The increase in public awareness initiatives and the growing preference of couples for these tests during IVF and other artificial insemination procedures are further driving the growth of the preimplantation genetic testing market in the region.
Companies playing a dominant role in the North America Preimplantation Genetic Testing Market profiled in this report are Illumina, Inc., Yikon Genomics, CooperSurgical, Oxford Gene Technology, Inc., Thermo Fisher Scientific, Inc., Rubicon Genomics, Inc., Agilent Technologies, Inc., Natera, Inc., Abbott Laboratories, PerkinElmer, Inc., and SciGene Corporation.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Procedure Type
5.1.2 Preimplantation Genetic Screening
5.1.3 Preimplantation Genetic Screening
5.1.4 Y-o-Y Growth Analysis, By Procedure Type
5.1.5 Market Attractiveness Analysis, By Procedure Type
5.1.6 Market Share Analysis, By Procedure Type
5.2.2 Next-Generation Sequencing
5.2.3 Polymerase Chain Reaction
5.2.4 Validation Biomarkers
5.2.5 Fluorescence in Situ Hybridization
5.2.6 Comparative Genomic Hybridization
5.2.7 Single-Nucleotide Polymorphism
5.2.8 Y-o-Y Growth Analysis, By Technology
5.2.9 Market Attractiveness Analysis, By Technology
5.2.10 Market Share Analysis, By Technology
5.3 Product and Service
5.3.2 Reagents and Consumables
5.3.4 Software and Services
5.3.5 Y-o-Y Growth Analysis, By Product and Service
5.3.6 Market Attractiveness Analysis, By Product and Service
5.3.7 Market Share Analysis, By Product and Service
5.4.3 Structural Chromosomal Abnormalities
5.4.4 Single Gene Disorders
5.4.5 X-Linked Disorders
5.4.6 HLA Typing
5.4.7 Gender Identification
5.4.8 Y-o-Y Growth Analysis, By Application
5.4.9 Market Attractiveness Analysis, By Application
5.4.10 Market Share Analysis, By Application
5.5 End users
5.5.2 Maternity Centers & Fertility Clinics
5.5.3 Hospitals, Diagnostic Labs, and Service Providers
5.5.4 Research Laboratories & Academic Institutes
5.5.5 Y-o-Y Growth Analysis, By End users
5.5.6 Market Attractiveness Analysis, By End users
5.5.7 Market Share Analysis, By End users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Procedure type
126.96.36.199 By Technology
188.8.131.52 By Product and Service
184.108.40.206 By Application
220.127.116.11 By End user
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Procedure type
126.96.36.199 By Technology
188.8.131.52 By Product and Service
184.108.40.206 By Application
220.127.116.11 By End user
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Procedure type
126.96.36.199 By Technology
188.8.131.52 By Product and Service
184.108.40.206 By Application
220.127.116.11 By End user
6.2 United States
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Illumina, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Thermo Fisher Scientific Inc.
8.3 Agilent Technologies, Inc.
8.4 Perkinelmer, Inc.
8.5 Coopersurgical, Inc.
8.6 ABBott Laboratories
8.7 Natera, Inc.
8.8 Rubicon Genomics, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.